A Multi-center, Randomized, Multiple-dose, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Abuse-deterrent Immediate-release Capsules Oxycodone Hydrochloride, Naltrexone Hydrochloride 1.5 mg or Oxycodone Hydrochloride, Naltrexone Hydrochloride 3.0 mg for the Treatment of Adults With Moderate to Severe Pain Following Bunionectomy Surgery

Trial Profile

A Multi-center, Randomized, Multiple-dose, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Abuse-deterrent Immediate-release Capsules Oxycodone Hydrochloride, Naltrexone Hydrochloride 1.5 mg or Oxycodone Hydrochloride, Naltrexone Hydrochloride 3.0 mg for the Treatment of Adults With Moderate to Severe Pain Following Bunionectomy Surgery

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Oct 2015

At a glance

  • Drugs Oxycodone/naltrexone (Primary)
  • Indications Postoperative pain
  • Focus Registrational; Therapeutic Use
  • Sponsors Elite Laboratories
  • Most Recent Events

    • 21 Oct 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 23 Jul 2015 Planned End Date changed from 1 Jul 2015 to 1 Aug 2015 as reported by ClinicalTrials.gov.
    • 23 Jul 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top